“Innovation” is suddenly the word on everybody’s lips.  Pfizer launched “Centers for Therapeutic Innovation”, Johnson and Johnson followed with their “Innovation Centres” and now Merck followed with their “Innovation hubs”.  In fact, it happened so fast that many of us in the dusty halls of academia are still trying to get a grip on what’s going on.  We got a view point from Dr. Andrew Johnson of the University of California and it seems like these things are innovative in more ways than one.  Here’s  a blog explaining what all this “innovation” is about.

Innovation and drug discoveryInnovation is the way forward for drug discovery and academic science. Image from www.european-coatings.com

The first thing you should know is that Innovation Centers are born out of necessity.  Patents are expiring on these drug company’s main earners while research and development costs have spiraled out of control.  Yet these companies still need to find new targets to develop into more life-saving, money-earning therapeutics.  Innovation Centers represent a radical shift in strategy that drug companies hope will allow them to deliver more while risking less.

The model goes something like this.  If the Innovation Center thinks the idea is a good one which has genuine potential to become a drug then, in principle, they are ‘in’.  As a friend in London described it, “it’s almost “Britain’s Got Talent” for scientists.  The details vary from company to company and project to project, but the stated intention is to take early stage projects as well as compounds closer to the clinic and thus create an externalised pipeline.   From that point the model is exciting in its flexibility with the company aiming to provide expertise uniquely targeted to the demands of the project.  In doing this, web-based platforms, such as Assay Depot, play a critical role.  Assay Depot enables rapid, cost-effective access to an exhaustive array of dedicated research services, technical experts and CROs, a vital requirement in a business where in house R&D is replaced with “on demand” activity.  For example, an innovation partnership might access lab space in an incubator, such as in “Biotech and Beyond” founded by Assay Depot CEO Kevin Lustig, or rapidly outsource aspects of drug development (such as DMPK, Pharmacology, medicinal chemistry etc) that would be beyond the scope of the average academic.  The critical part of the innovation model is that the ties in this partnership are weak and flexible.  The drug company can get in quick on a new target and get out just as fast if the target proves to be a dud.

What this means for the researcher on the bench and ultimately what it will mean for drug discovery are still open-ended ideas. In theory Innovation Centers offer a much needed new source of funding and know-how for applied science as well as an entrepreneurial career route distinct from academia.  On the other hand the locations of these centers (San Francisco, Boston, New York and London)  is currently not very innovative and so surely casting a wider net and preventing competition for the same targets will require the geographical expansion of the centers, to include China and India for example.   In the end proof of lasting success of these Innovation Centers will be measured in the number and value of new products brought to the healthcare market.   


1)  “Search and Development”,Editorial, Nature Biotechnology, vol. 32, p109

Posted 1:06 pm,

Sometimes, in tragic circumstances, a lesson can be learned and applied in unexpected ways. That appears to be the case with a rare disease that produces debilitating symptoms in children – but might also offer clues to developing a new class of antivirals. The particular disease, an extremely rare congenital disorder called CDG-IIb,  affects the […]

Posted 9:52 am,

We have recently discussed here how crowdfunding — donations from the general public in support of a cause, idea, or invention — has caught the attention of scientists seeking financial backing in an era of tight budgets. The brave new world of crowdfunding in science raises questions that defy easy answers. What is essential to […]

Posted 12:28 pm,

Connecting academic scientists to the global life science ecosystem Like everyone else, academic researchers are finding that funding sources are drying up and that they somehow must do more research work with less money. To do something about it, a group of Universities in Missouri and Kansas have teamed up with Assay Depot to create […]

Posted 11:39 am,

As we previously discussed, CRISPR-mania is sweeping the globe. (Okay, it might not be as big as Beatlemania, but more than a few life science researchers have probably squealed in delight.) The CRISPR system, derived from bacteria’s fight against viruses and tailored so that it can snip away genetic material in other organisms, has generated […]

Posted 2:26 pm,

It’s a sad story that everyone is familiar with: A patient takes one or more well-known cancer drugs, and they work — for a while. However, after the respite, the cancer comes roaring back, this time impervious to the once powerful effects of the cancer drugs. Many people would view the disease’s return with resignation […]

Posted 1:52 pm,

Over the course of this series so far we’ve looked at the role of the microbiome in two of the three major therapeutic areas targeted by drug discoverers.  Now comes the third and final segment and it’s a big one:  Cancer.  For many people the role of the microbiome in inflammation and metabolism is unsurprising.  Your […]

Posted 4:08 pm,

The vast majority of compounds that enter clinical trials fail to make it through. The result: few drugs, plenty of bills. The consensus in drug discovery is that things need to change. Part of the problem is the maze that is human biology. Choosing the “right” drug target is difficult when 1) information is incomplete, […]

Posted 11:07 am,

Outsourcing has proven to reduce costs while dramatically improving productivity of the drug discovery process. Primary benefits to outsourcing drug discovery include higher quality services, direct cost savings, reduced time to clinic, and enhanced innovation. [1] Case in point: Anika Therapeutics recently won FDA Pre-Market Approval for the new osteoarthritis treatment, Monovisc. One of the […]

Posted 10:55 am,

Having introduced the “Age of the Microbiome in Drug Discovery” and the “The Microbiome in Metabolic Disease” we now turn to the influence of the microbiome in inflammation.  Dr. Andrew Johnson of the University of California again gave us his thoughts on this emergent therapeutic area. There is little need for an introduction into the […]

Posted 1:47 pm,